Literature DB >> 17041910

Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.

Christophe Béroud1, Sylvie Tuffery-Giraud, Masafumi Matsuo, Dalil Hamroun, Véronique Humbertclaude, Nicole Monnier, Marie-Pierre Moizard, Marie-Antoinette Voelckel, Laurence Michel Calemard, Pierre Boisseau, Martine Blayau, Christophe Philippe, Mireille Cossée, Michel Pagès, François Rivier, Olivier Danos, Luis Garcia, Mireille Claustres.   

Abstract

Approximately two-thirds of Duchenne muscular dystrophy (DMD) patients show intragenic deletions ranging from one to several exons of the DMD gene and leading to a premature stop codon. Other deletions that maintain the translational reading frame of the gene result in the milder Becker muscular dystrophy (BMD) form of the disease. Thus the opportunity to transform a DMD phenotype into a BMD phenotype appeared as a new treatment strategy with the development of antisense oligonucleotides technology, which is able to induce an exon skipping at the pre-mRNA level in order to restore an open reading frame. Because the DMD gene contains 79 exons, thousands of potential transcripts could be produced by exon skipping and should be investigated. The conventional approach considers skipping of a single exon. Here we report the comparison of single- and multiple-exon skipping strategies based on bioinformatic analysis. By using the Universal Mutation Database (UMD)-DMD, we predict that an optimal multiexon skipping leading to the del45-55 artificial dystrophin (c.6439_8217del) could transform the DMD phenotype into the asymptomatic or mild BMD phenotype. This multiple-exon skipping could theoretically rescue up to 63% of DMD patients with a deletion, while the optimal monoskipping of exon 51 would rescue only 16% of patients. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17041910     DOI: 10.1002/humu.20428

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  71 in total

Review 1.  Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors:  Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

Authors:  Qi-Long Lu; Toshifumi Yokota; Shin'ichi Takeda; Luis Garcia; Francesco Muntoni; Terence Partridge
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

3.  Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.

Authors:  Toshifumi Yokota; Qi-Long Lu; Terence Partridge; Masanori Kobayashi; Akinori Nakamura; Shińichi Takeda; Eric Hoffman
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

Review 4.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

Review 5.  Circular RNAs in myogenesis.

Authors:  Arundhati Das; Aniruddha Das; Debojyoti Das; Kotb Abdelmohsen; Amaresh C Panda
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-04-01       Impact factor: 4.490

Review 6.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

7.  Exon exchange approach to repair Duchenne dystrophin transcripts.

Authors:  Stéphanie Lorain; Cécile Peccate; Maëva Le Hir; Luis Garcia
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

8.  Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy.

Authors:  Laura van Vliet; Christa L de Winter; Judith C T van Deutekom; Gert-Jan B van Ommen; Annemieke Aartsma-Rus
Journal:  BMC Med Genet       Date:  2008-12-01       Impact factor: 2.103

9.  Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.

Authors:  Takashi Saito; Akinori Nakamura; Yoshitsugu Aoki; Toshifumi Yokota; Takashi Okada; Makiko Osawa; Shin'ichi Takeda
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

10.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Eduard Gappmaier; Michael T Howard; Jacinda B Sampson; Jerry R Mendell; Cheryl Wall; Wendy M King; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Carrie M Stephan; Karla S Laubenthal; Brenda L Wong; Paula J Morehart; Amy Meyer; Richard S Finkel; Carsten G Bonnemann; Livija Medne; John W Day; Joline C Dalton; Marcia K Margolis; Veronica J Hinton; Robert B Weiss
Journal:  Hum Mutat       Date:  2009-12       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.